Last updated: February 26, 2026
What is the current development stage of PF-07321332?
PF-07321332, also known as Paxlovid, is an oral antiviral developed by Pfizer targeting SARS-CoV-2. It received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) in December 2021 and full approval in August 2022.
It is currently in widespread distribution, with ongoing studies to evaluate long-term safety, efficacy in diverse populations, and potential combination therapies. Pfizer continues to monitor post-marketing data, with Phase IV studies assessing real-world effectiveness.
What are recent clinical trial outcomes and regulatory milestones?
Clinical Trial Results
- Phase II/III trial: Reported a 89% reduction in hospitalization or death when administered within five days of symptom onset.
- Sample size: Over 2,200 high-risk patients.
- Endpoints: Efficacy in preventing severe disease; safety profile confirms tolerability.
Regulatory Milestones
- EUA: Granted in U.S., Dec 2021.
- Full FDA approval: August 2022.
- EMA approval: Approved for use in the European Union in February 2023.
- Other jurisdictions: Awaiting approvals or under review in Canada, Australia, Japan, and other markets.
What are production and supply chain considerations?
Pfizer has increased manufacturing capacity:
- 2022 production: Estimated 10 million courses.
- 2023 targets: Expand to 20 million courses.
- Global distribution: Secured supply agreements with countries across North America, Europe, and Asia.
Supply chain issues reported early in deployment have been addressed through diversified sourcing, increased raw material inventory, and logistics optimization.
How does PF-07321332 compare with other COVID-19 antivirals?
| Candidate |
Developer |
Approval Status |
Route |
Dosing |
Efficacy (Hospitalization reduction) |
Side Effects |
| PF-07321332 (Paxlovid) |
Pfizer |
EUA/Full |
Oral |
300 mg BID for 5 days |
89% |
Mild to moderate, includes dysgeusia, diarrhea |
| Molnupiravir |
Merck |
EUA |
Oral |
800 mg BID for 5 days |
30% |
Mostly mild, includes diarrhea, nausea |
| Remdesivir |
Gilead |
Approved |
IV |
200 mg on day 1, then 100 mg daily |
6% |
Mild, including nausea, elevated liver enzymes |
Paxlovid's higher efficacy and oral administration position it favorably for outpatient use.
What is the projected market size and growth trajectory?
Market size estimates:
- 2022 global sales: $5 billion.
- 2023 forecast: $8-10 billion.
- Target patient population: Estimated 100 million high-risk COVID-19 cases globally annually.
Drivers for growth:
- Continued COVID-19 evolution leading to variants less responsive to vaccines.
- Expanding approvals to more countries.
- Emphasis on outpatient management saving healthcare resources.
Challenges:
- Emergence of resistant variants.
- Competition from other antivirals and treatments.
- Pricing and reimbursement considerations in different markets.
What are future development and commercialization plans?
Pfizer plans to:
- Conduct real-world effectiveness studies.
- Expand indications to pediatric and immunocompromised populations.
- Explore combination therapies with other antivirals.
- Collaborate with global health organizations to improve access in low-income countries.
What is the outlook for the antiviral market?
The antiviral segment in the COVID-19 landscape is consolidating. Despite the emergence of resistance, Pfizer's Paxlovid maintains a dominant position due to its efficacy, oral route, and regulatory approvals. The market is expected to sustain growth driven by vaccine efficacy waning, new variants, and preparedness for future pandemics.
Key Takeaways
- PF-07321332 (Paxlovid) is in widespread use with ongoing studies confirming safety and efficacy.
- It has received full regulatory approval in the U.S. and approval in Europe.
- Production capacity is set to double in 2023, broadening access.
- Competition remains from other antivirals, but Paxlovid's profile favors ongoing market leadership.
- The global market for COVID-19 antivirals could reach $10 billion in 2023.
FAQs
1. When did PF-07321332 receive FDA full approval?
August 2022.
2. How effective is Paxlovid in preventing severe COVID-19?
Clinical trials show an approximately 89% reduction in hospitalization or death if administered early.
3. What are the main challenges facing Paxlovid’s market?
Variant resistance, manufacturing capacity, access in low-income countries, and competition.
4. Are there ongoing studies for pediatric use?
Yes, Pfizer is conducting trials for pediatric populations.
5. How does the efficacy of Paxlovid compare to molnupiravir?
Paxlovid reduces severe outcomes by roughly three times more than molnupiravir based on trial data.
References
[1] U.S. Food and Drug Administration. (2022). FDA Approves Pfizer’s Paxlovid for the Treatment of COVID-19.
[2] European Medicines Agency. (2023). EMA approves Paxlovid for COVID-19.
[3] Pfizer. (2022). Paxlovid (nirmatrelvir and ritonavir) Fact Sheet for Healthcare Providers.
[4] Merck. (2022). Efficacy and Safety Data for Molnupiravir.
[5] Gilead Sciences. (2021). Remdesivir approvals and studies.
